Plain-English translation of NCT06755151 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term safety study for people with primary biliary cholangitis (PBC), a chronic condition affecting the bile ducts in the liver. The study tests combined with ursodeoxycholic acid — two medications that may help protect the liver. Researchers want to understand how safe and well-tolerated this medication combination is when used together over an extended period.
Primary biliary cholangitis causes progressive damage to bile ducts, and current treatments don't work well enough for everyone. This medication combination has shown promise in earlier studies, and researchers now want to confirm it is safe and tolerable to use long-term in real-world patient populations.
You likely qualify if…
You likely don't qualify if…
You will take the two medications as prescribed while researchers monitor your safety through regular visits and blood tests over an extended period. Since this is a long-term study, you should be prepared for ongoing clinic visits to check how you are doing and whether you are experiencing any side effects. The study is 'open label,' meaning you and your doctor will know you are receiving this specific medication combination.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Xijing Hospital of Digestive Diseases
Enrollment target
~300 participants
Started
January 2024
Primary completion
December 2035
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yansheng Liu
Xijing Hospital of Digestive Diseases
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.